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OBJECTIVE—Genome-wide association studies have identified
several variants within the MTNR1B locus that are associated
with fasting plasma glucose (FPG) and type 2 diabetes. We
refined the association signal by direct genotyping and examined
for associations of the variant displaying the most independent
effect on FPG with isolated impaired fasting glycemia (i-IFG),
isolated impaired glucose tolerance (i-IGT), type 2 diabetes, and
measures of insulin release and peripheral and hepatic insulin
sensitivity.
RESEARCH DESIGN AND METHODS—We examined Euro-
pean-descent participants in the Inter99 study (n  5,553), in a
sample of young healthy Danes (n  372), in Danish twins (n 
77 elderly and n 97 young), in additional Danish type 2 diabetic
patients (n  1,626) and control subjects (n  505), in the Data
from the Epidemiological Study on the Insulin Resistance Syn-
drome (DESIR) study (n  4,656), in the North Finland Birth
Cohort 86 (n  5,258), and in the Haguenau study (n  1,461).
RESULTS—The MTNR1B intronic variant, rs10830963, carried
most of the effect on FPG and showed the strongest association
with FPG (combined P  5.3  1031) and type 2 diabetes. The
rs10830963 G-allele increased the risk of i-IFG (odds ratio [OR]
1.64, P  5.5  1011) but not i-IGT. The G-allele was associated
with a decreased insulin release after oral and intravenous
glucose challenges (P  0.01) but not after injection of tolbut-
amide. In elderly twins, the G-allele associated with hepatic
insulin resistance (P  0.017).
CONCLUSIONS—The G-allele of MTNR1B rs10830963 in-
creases risk of type 2 diabetes through a state of i-IFG and not
through i-IGT. The same allele associates with estimates of -cell
dysfunction and hepatic insulin resistance. Diabetes 58:1450–
1456, 2009
The neurohormone melatonin is the main secre-tory product of the pineal gland and is mainlyinvolved in the regulation of circadian rhythms.Melatonin has been proposed to influence both
insulin secretion and endogenous glucose production
(1,2). Interestingly, melatonin secretion is reported to be
impaired in type 2 diabetic patients (2,3).
The effect of melatonin is mediated by the membrane
receptors melatonin receptor 1 (MT1; encoded by
MTNR1A) and melatonin receptor 2 (MT2; encoded by
MTNR1B), which both belong to the seven-transmem-
brane G protein–coupled receptor superfamily (4).
MTNR1B is abundantly expressed in the retina and the
suprachiasmatic nucleus and the circadian rhythm control
center (5), and the association with glucose homeostasis
might be mediated indirectly through the brain. However,
MTNR1B is also expressed in human pancreatic islets
(6,7) and pancreatic -cells (8), and MTNR1B mRNA
expression is upregulated in pancreatic tissue of type 2
diabetic patients compared with control subjects (7),
suggesting a putative direct role of melatonin on -cell
function.
In a recent genome-wide association study involving
2,151 nondiabetic French individuals, we identified
rs1387153, located 28 kb upstream of the 5 region of
MTNR1B at chromosome 11q21-q22 as a modulator of
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fasting plasma glucose (FPG) (8). Additional analyses in
16,094 Europeans confirmed that the rs1387153 T-allele
associated with both increased FPG and risk of type 2
diabetes (8). Concurrently, similar findings were reported
(9,10). Using in silico imputation from the HapMap study
in their overall meta-analysis, Prokopenko et al. (9) also
suggested that the MTNR1B intronic variant, rs10830963,
which is in substantial linkage disequilibrium (LD) with
rs1387153 (r2  0.7), shows the strongest signal to FPG.
In the present study, we initially aimed to refine the
association signal within the 62-Kb LD block that includes
MTNR1B. This was done by direct genotyping of addi-
tional single-nucleotide polymorphisms (SNPs) in LD
(r2  0.70) with rs1387153 (including rs10830963) in large
European populations. We then evaluated the association
of the SNP displaying the most associated and indepen-
dent signal with isolated impaired fasting glycemia (i-IFG)
and isolated impaired glucose tolerance (i-IGT). Finally,
we examined for potential associations of the marker SNP
with glucose- and tolbutamide-stimulated insulin release
and measures of both peripheral and hepatic insulin
sensitivity.
RESEARCH DESIGN AND METHODS
Study participants: DESIR. Associations between genotype and quantita-
tive metabolic traits were studied in the Data from the Epidemiological Study
on the Insulin Resistance Syndrome (DESIR) cohort, which is a longitudinal
French general population that was fully described elsewhere (11,12). Among
them, 3,411 individuals had been followed for the incidence of IFG and type 2
diabetes during 9 years (n  517 incident cases), and 4,589 had been analyzed
for the association with A1C level. Clinical characteristics are found in an
online-only appendix at http://diabetes.diabetesjournals.org/cgi/content/full/
db08–1660/DC1, supplementary Table 1.
NFBC86. Associations between genotype and quantitative metabolic traits
were studied in the Northern Finland 1986 Birth Cohort (NFBC86), which is a
prospective 1-year birth cohort including all Finnish Caucasian mothers with
children whose expected date of birth fell between 1 July 1985 and 30 June
1986 in the two northernmost provinces of Finland (13). Clinical characteris-
tics are found in the online appendix, supplementary Table 1.
Haguenau. Associations between genotype and quantitative metabolic traits
were studied in the Haguenau community-based cohort of young adults that
investigates long-term consequences of being born small for gestational age
and was fully described elsewhere (14). At a mean age of 22 years, participants
under overnight fasting conditions underwent a medical examination to
assess anthropometric and clinical parameters, including an oral glucose
tolerance test (OGTT) with a glucose load of 75 g, and further blood samples
were taken after 30 and 120 min for measurement of plasma glucose. Clinical
characteristics are given in the online appendix, supplementary Table 1.
Inter99. Associations between genotype and quantitative metabolic traits
were studied in the population-based Inter99 sample of middle-aged people
(clinicaltrials.gov reg. no. NCT00289237) (15,16). Individuals with normal
glucose tolerance (NGT; n  4,400), i-IFG (n  485), i-IGT (n  464), or both
IFG and IGT (IFG/IGT, n  201) were investigated for associations between
genotype and quantitative metabolic traits. Patients in the Inter99 sample with
type 2 diabetes (n  322) were not included in the present analysis of
quantitative traits. Clinical characteristics are shown in online appendix
supplementary Table 2.
Young healthy Danes. Studies of quantitative metabolic traits were per-
formed in 372 young healthy Danes characterized by a combined intravenous
glucose tolerance test (IVGTT) and intravenous tolbutamide challenge re-
cruited at the Research Centre for Prevention and Health (17) (online
appendix supplementary Table 2).
The twin study. Studies of quantitative metabolic traits were further per-
formed in two population-based samples of elderly (monozygotic n  38,
dizygotic n  39) and young (monozygotic n  58, dizygotic n  40) twins
characterized by an IVGTT followed by a 2-h hyperinsulinemic-euglycemic
clamp (18) (online appendix Table 2).
All participants from Inter99, the young healthy Danish study population,
and the twin study were of Danish nationality and European descent.
IFG, IGT, and type 2 diabetic case subjects. The Danish case-control
studies of IFG, IGT, and type 2 diabetes included all unrelated IFG, IGT, and
type 2 diabetic case subjects and all NGT control subjects from the Inter99
cohort as well as samples recruited from the outpatient clinic at the Steno
Diabetes Center (NGT  505, type 2 diabetes  1,626). The French case-
control study of type 2 diabetes included 2,622 unrelated type 2 diabetic
patients ascertained from the French type 2 diabetic family cohort recruited in
the CNRS-UMR8090 Unit (Lille, France), the Endocrinology-Diabetology De-
partment of the Corbeil-Essonnes Hospital (Evry, France), and the DESIR
cohort. A total of 4,343 DESIR participants were included as control subjects.
Control subjects had normal fasting glycemia and were glucose tolerant
after a World Health Organization–standardized OGTT. Type 2 diabetes, IFG,
and IGT were defined according to the World Health Organization 1999
criteria (19).
Ethics. In the mentioned study samples, informed written consent was
obtained from all study participants before any investigations. All studies were
approved by the local ethics committees and were in accordance with the
principles of the Helsinki Declaration II.
Biochemical and anthropometrical measurements. Methods and condi-
tions for biochemical and anthropometrical measurements are described in
the online appendix.
Genotyping. The recombination rate based on HapMap data defines a region
that includes MTNR1B and its 5 region flanked by two recombination hot
spots (Fig. 1). In DESIR, NFBC86, and Haguenau, we genotyped all common
SNPs (HapMap data, n  7) in high LD (r2  0.70) with rs1387153: six are
located in the 5 region of MTNR1B (rs7112766 [LD with rs1387153 r2  0.86],
rs11523890 [r2 0.82], rs10830956 [r2 1.0], rs10765573 [r2 0.82], rs7936247
[r2  0.84], and rs11020124 [r2  0.94]) and one SNP rs10830963 (r2  0.70) is
located in the only intron of MTNR1B (Fig. 1). Genotyping of all SNPs was
performed using Taqman allelic discrimination. Inter99, the young Danish
sample set and twin populations were genotyped for rs10830963. Genotype
success rate was at least 96%, and no deviation (P  0.05) from Hardy-
Weinberg equilibrium was observed in any of the examined populations.
Statistical analysis. We analyzed the effect of all eight SNPs on FPG (and in
the case of rs10830963 also for additional metabolic quantitative traits) in
nondiabetic subjects, using linear regression models under the additive model
adjusted for age, sex, and BMI. The estimates of each SNP effect on FPG and
their standard errors for each separate analysis were combined in the
meta-analyses using the weighted inverse normal method. The overall effect
and its confidence interval were estimated using the inverse variance method
implemented in the meta.summaries function of the R rmeta package. The
effect of each SNP on diabetes status was tested in a logistic regression model
applying the R mgcv package, adjusted for age, sex, and BMI. In the DESIR
participants, we assessed the effect of each SNP on IFG or diabetes incidence
with Cox proportional hazards regression models, adjusted for sex and BMI.
Survival time was age at diagnosis or censoring. The statistical analyses in the
DESIR, NFBC86, and Haguenau study samples were performed with R
(version 2.7.2), combined with the survival rmeta and mgcv packages.
To examine the impact of rs10830963 in comparison to the effects of each
of the other associated SNPs, we analyzed in each population separately four
haplotypes using the THESIAS genetic model program (20) (online appendix
supplementary Table 4). This method estimates likelihood of specified models
for haplotype effects, under the general linear model framework, and allows
testing of constrained models. This analysis aimed at testing two-SNP models
while accounting for the high correlation between SNPs (unlike a plain
two-loci regression model).
RESULTS
SNP rs10830963 shows the strongest and most
independent effect on FPG. We analyzed the associ-
ation between all seven genotyped SNPs (Fig. 1; see
details in RESEARCH DESIGN AND METHODS) and FPG in
nondiabetic participants from the DESIR (mean age 47
years), NFBC86 (mean age 16 years), and Haguenau
(mean age 22 years) cohorts. Applying an additive
genetic model adjusted for age, sex, and BMI, the
rs10830963 G-allele showed the strongest association
with increased FPG in each study taken individually and
in the combined meta-analyses (n  11,375;   0.07
mmol/l, 95% CI 0.06–0.08; combined P  5.3  1031)
(Fig. 1 and online appendix supplementary Table 3). In
the combined sample, the inclusion of rs10830963 in the
regression models of the other SNPs annulled their
effect on FPG (P  0.12). By constraining the effect of
rs10830963, we found significant differences between
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models of haplotype analyses. In contrast, when we
constrained the effects of any of the others SNPs, we
found no significant differences (online appendix sup-
plementary Table 4). These data confirm an indispens-
able effect of rs10830963 in the association with FPG.
G-allele of rs10830963 associates not only with in-
creased risk of diabetes but also with impaired fast-
ing glycemia. In the Danish case-control study, involving
1,948 type 2 diabetic case subjects and 4,905 glucose-
tolerant control subjects, the rs10830963 G-allele of
MTNR1B was significantly associated with increased risk
of type 2 diabetes (odds ratio [OR] 1.23, 95% CI 1.10–1.37,
P  0.00036) (Table 1).
In the French case-control samples, the same allele
also showed the strongest association with increased
risk of type 2 diabetes in studies of 2,622 case subjects
and 4,343 nondiabetic control subjects (OR 1.19, 95% CI
1.08–1.32; P  0.00048) (online appendix supplementary
Table 5).
Interestingly, in the Inter99 population-based sample of
middle-aged Danes, the same G-allele associated with
increased risk of having i-IFG (OR 1.64, 95% CI 1.43–1.90,
P  5.511) and increased risk of combined IFG/IGT (OR
1.35, 95% CI 1.08–1.69, P  0.0085; Table 1). In addition,
prospective data from the DESIR cohort demonstrated
that the G-allele of rs10830963 predicted the incidence of
IFG after a 9-year period (hazard ratio 1.24, 95% CI
1.06–1.45; P  0.007) (Table 1).
rs10830963 impacts on glycemia, insulin release, and
hepatic insulin sensitivity. The impact of MTNR1B
rs10830963 on diabetes-related quantitative traits was in-
vestigated after an OGTT in two population-based cohorts:
the Inter99 study (mean age 46 years) and the Haguenau
study. Assuming an additive genetic model, carriers of the
minor G-allele of rs10830963 demonstrated an increased
plasma glucose level 30 min post-OGTT in Inter99 and
Haguenau (  0.2 mmol/l, 95% CI 0.1–0.2, P  2  107
[Table 2]; and   0.2 mmol/l, 95% CI [0.09–0.3], P 4.1
104 [online appendix supplementary Table 6],
respectively).
In addition, an allele-dependent increase in A1C level
was found for carriers of the minor G-allele of rs10830963
in the Inter99 and DESIR cohorts (  0.03%, 95% CI
0.02–0.05, P  0.00011 [Table 2]; and   0.03%, 95% CI
0.02–0.05, P  0.00027 [data not shown], respectively).
In the Inter99 study population, carriers of the minor
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FIG. 1. Genomic context and recombination rate of the eight associated SNPs at the MTNR1B locus with FPG. The upper panel shows the LD
structure of the 621-kb LD block in the CEU population from HapMap phase II using the Haploview software. The lower panel shows the
association magnitude (log P value) with FPG of the eight SNPs and the recombination rate (%) at the MTNR1B locus.
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G-allele of rs10830963 showed a decreased serum insulin
level 30 min post-OGTT (2.4%, 95% CI 0.3–4.6, P  0.025)
and a decreased insulin release as assessed by the insuli-
nogenic index (5.0%, 95% CI 1.9–8.0, P  0.0016) and
BIGTT–acute insulin response (AIR) (6.2%, 95% CI 4.5–8.0,
P 4.3 1012) (Table 2). No associations with surrogate
measures of insulin resistance were found.
In the Haguenau cohort, these findings were substanti-
ated: decreased serum insulin 30 min post-OGTT ( 
5.8%, 95% CI 1.0–10.4; P  0.02) and decreased insulino-
genic index (  4.4%, 95% CI 1.5–7.3; P  0.003; online
appendix supplementary Table 6).
In the study of 372 young healthy Danes (mean age 25
years), carriers of the rs10830963 G-allele showed an
impairment of acute serum insulin response (P  0.0022)
as well as a decreased disposition index (P  0.021) after
an intravenous glucose load (Table 3). We found no
association of the genotype with the Bergman minimal
model–derived insulin sensitivity index. After the IVGTT,
each individual had an intravenous injection of tolbut-
amide to elicit a secondary -cell response. No difference
in the tolbutamide-induced insulin response was shown
when stratifying the individuals according to the
rs10830963 genotype (P  0.60) (Table 3).
In a population of 77 elderly Danish twins (mean age 62
years), who underwent an IVGTT and a 2-h hyperinsuline-
mic-euglycemic clamp, the association between the minor
G-allele of MTNR1B rs10830963 and decreased acute
plasma insulin response was confirmed (P  0.0077)
(Table 4). In addition, the G-allele carriers had decreased
TABLE 1
Association studies of MTNR1B rs10830963 in the Danish population-based Inter99 sample, in individuals sampled at Steno Diabetes
Center, and in the French DESIR cohort in relation to glucose tolerance status
Glucose tolerant i-IFG i-IGT
Both IFG and
IGT Type 2 diabetes
n (men/women) 4,905 (2,277/2,628) 485 (356/129) 464 (196/268) 201 (130/71) 1,948 (1,200/748)
CC 2,644 (53.9%) 196 (40.4%) 282 (60.8%) 106 (52.7%) 1,002 (51.4%)
CG 1,913 (39%) 230 (47.4%) 151 (32.5%) 66 (32.8%) 776 (39.8%)
GG 348 (7.1%) 59 (12.2%) 31 (6.7%) 29 (14.4%) 170 (8.7%)
G-allele frequency (%) 26.6 36.0 23.0 30.8 28.6
OR per G-allele (95% CI) 1.64 (1.41–1.89) 0.85 (0.72–1.00) 1.35 (1.08–1.69) 1.23 (1.10–1.37)
Padd 5.5  10
11 0.051 0.0085 0.00036
French DESIR cohort (n  3,411) Incidence of IFG
(n  334)
Incidence of type 2
diabetes (n  183)
Hazard ratio (95% CI) 1.24 (1.06–1.45) 1.02 (0.80–1.25)
Padd 0.007 0.87
In the Danish study populations, data are n (%), number of subjects stratified according to MTNR1B rs10830963, G-allele frequency in %, and
OR (95% CI) per allele. P values compare genotype distribution between case subjects (i-IFG, i-IGT, both IFG and IGT, and type 2 diabetes),
and glucose-tolerant control subject applying an additive genetic model while adjusting for age, sex, and BMI. In the French DESIR cohort,
the incidence of IFG or diabetes was defined as fasting plasma glucose 6.1 mmol/l or treatment with antidiabetic agents after a 9-year
follow-up period.
TABLE 2
Quantitative metabolic traits during an OGTT in the Danish population-based Inter99 sample of 5,553 middle-aged and nondiabetic
individuals stratified according to the MTNR1B rs10830963 genotype
rs10830963 CC CG GG
Effect per allele
(95% CI) Padd
n (men/women) 2,950 (1,410/1,540) 2,167 (1,101/1,066) 436 (211/225)
Age (years) 46 8 46 8 46 8
BMI (kg/m2) 26.1 4.5 25.9 4.3 26  4.1 0.1 (0.3 to 0.08) 0.26
Plasma glucose (mmol/l)
Fasting 5.41 0.5 5.48 0.51 5.59 0.54 0.09 (0.07 to 1.1) 1  1021
30 min post-OGTT 8.48 1.67 8.62 1.75 8.83 1.63 0.2 (0.1 to 0.2) 2  107
120 min post-OGTT 6.01 1.55 5.83 1.51 6.1 1.56 0.03 (0.09 to 0.03) 0.35
Serum insulin (pmol/l)
Fasting 34 (24–50) 33 (23–49) 35 (24–52) 0.3 (2.4 to 1.9) 0.81
30 min post-OGTT 251 (181–359) 240 (171–343) 243 (174–351) 2.4 (4.5 to0.3) 0.025
120 min post-OGTT 155 (98–247) 147 (88–234) 162 (105–286) 0.5 (2.5 to 3.5) 0.75
Insulinogenic index 75 (47–127) 71 (44–117) 68 (46–106) 5.0 (8.0 to1.9) 0.0016
BIGTT-AIR 1,699 (1,342–2,160) 1,576 (1,258–2,007) 1,515 (1,223–1,909) 6.2 (8.0 to4.5) 4.3  1012
BIGTT-Si 9.4 4.0 9.6 5.9 9.0 3.9 0.8 (0.25 to 0.09) 0.37
HOMA-IR 8.1 (5.5–12.2) 8.0 (5.4–12.2) 8.6 (6.0–13.4) 1.3 (0.9 to 3.6) 0.23
A1C (%) 5.78 0.4 5.82 0.41 5.82 0.38 0.03 (0.02 to 0.05) 0.00011
Data are means  SD or medians (interquartile range). Type 2 diabetic patients have been excluded from the present quantitative trait
analyses. Values of serum insulin, homeostasis model assessment of insulin resistance (HOMA-IR), insulinogenic index, and BIGTT-AIR were
logarithmically transformed before statistical analysis, and their effect sizes are presented as the increase/decrease in percent. Calculated P
values and effect sizes were adjusted for age (BIGTT-AIR and BIGTT-Si); age and sex (BMI); or age, sex, and BMI (all other traits) assuming
an additive genetic model. Calculations of HOMA-IR and the insulinogenic index are described in the online appendix. BIGTT-AIR and
BIGTT-S
i
are calculated as described elsewhere (21).
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plasma insulin levels 30 min after an IVGTT (P  0.035).
The MTNR1B genotype was not associated with clamp-
derived measures of peripheral insulin sensitivity (Rd);
however, carriers of the G-allele were less likely to de-
crease their hepatic glucose production during insulin
infusion (P  0.017) (Table 4). We failed to show any
significant associations of MTNR1B genotype to measures
of insulin sensitivity and hepatic glucose production in the
sample of young twins (mean age 28 years) (data not
shown).
TABLE 3
Quantitative metabolic traits during an IVGTT in the population-based sample of 372 young healthy Danes stratified according to the
MTNR1B rs10830963 genotype
rs10830963 CC CG GG
Effect per allele
(95% CI) Padd
n (men/women) 200 (104/96) 146 (72/74) 26 (8/18)
Age (years) 25 3 26  4 26  4
BMI (kg/m2) 23.2 3.5 23.9 4.0 24.9 3.8 0.7 (0.1 to 1.3) 0.016
Fasting plasma glucose
(mmol/l) 4.92 0.43 5.06 0.47 5.17 0.77 0.1 (0.07 to 0.2) 0.00015
Fasting serum insulin
(pmol/l) 30 (23–45) 30 (23–46) 37 (29–51) 0.006 (0.09 to 0.07) 0.97
Acute serum insulin
response 0–8 min
(pmol/l  min) 2,098 (1,297–3,018) 1,642 (1,135–2,548) 2,172 (1,387–2,621) 0.7 (1.1 to0.2) 0.0022
Acute serum insulin
response 0–10 min after
tolbutamide
injection (pmol/l  min) 1,399 (765–2,248) 1,376 (870–2,022) 2,036 (1,357–2,588) 0.1 (0.3 to 0.5) 0.60
Insulin sensitivity index
(105  (min) 
pmol/l)1) 13.5 (9.0–19.3) 13.3 (9.0–20.3) 11.1 (7.5–14.8) 0.02 (0.05 to 0.09) 0.65
Disposition index 28,760 (16,810–41,470) 24,030 (16,480–33,730) 23,900 (15,470–27,910) 1.3 (2.3 to0.2) 0.021
Data are means  SD (age, BMI, and plasma glucose) or medians (interquartile range). Values of fasting serum insulin, acute serum insulin
response 0–8 min, acute serum insulin response 0–10 min after tolbutamide injection, insulin sensitivity index, and disposition index were
transformed using cube root before statistical analysis, and their effect sizes are presented as the increase/decrease on a cubic scale.
Calculated P values and effect sizes were adjusted for age, sex, and BMI (except for BMI) assuming an additive model. Acute serum insulin
response 0–10 min after tolbutamide injection was in addition adjusted for plasma glucose values before the injection of tolbutamide. Acute
serum insulin response 0–8 min, acute serum insulin response 0–10 min after tolbutamide injection, insulin sensitivity index, and disposition
index are calculated as described elsewhere (17) and in the online appendix.
TABLE 4
Quantitative metabolic traits during an IVGTT followed by a hyperinsulinemic-euglycemic clamp in the population-based sample of
77 elderly Danish twins stratified according to MTNR1B rs10830963 genotype
rs10830963 CC CG GG
Effect per allele
(95% CI) Padd
n (men/women) 38 (20/18) 36 (13/23) 3 (0/3)
Age (years) 62 2 62  2 62  2
BMI (kg/m2) 27.5 4.2 25.3 4.5 22.0 0.9 2.5 (4.4 to0.6) 0.015
Plasma glucose (mmol/l)
Fasting 5.8 1.2 5.5 1.1 6.3 1.2 0.06 (0.4 to 0.3) 0.72
10 min post-IVGTT 14.2 1.2 13.9 1.1 15.0 0.5 0.3 (0.1 to 0.8) 0.15
30 min post-IVGTT 11.2 1.3 11.1 1.1 12.0 0.7 0.5 (0.003 to 1.1) 0.055
Plasma insulin (pmol/l)
Fasting 34 (19–52) 24 (16–34) 19 (19–21) 0.03 (0.2 to 0.2) 0.74
10 min post-IVGTT 165 (111–288) 94 (67–125) 86 (37–98) 0.3 (0.7 to 0.03) 0.075
30 min post-IVGTT 108 (71–170) 75 (55–96) 63 (29–82) 0.3 (0.5 to0.03) 0.035
Acute serum insulin response
0–10 min (pmol/l  min) 1,802 (1,389–3,724) 1,144 (739–1,690) 855 (99–1,433) 0.5 (0.9 to0.2) 0.0077
Basal (mg  kg1  min1)
Hepatic glucose production 3.1 0.4 3.0 0.3 3.2 0.8 0.1 (0.3 to 0.03) 0.13
Clamp (mg  kg1  min1)
Glucose disposal rate (Rd) 9.0  3.3 9.8 2.7 15.7 3.6 1.0 (0.4 to 2.2) 0.18
Hepatic glucose production 1.5 0.7 1.7 0.5 2.9 1.7 0.4 (0.07 to 0.6) 0.017
Data are means  SD or medians (interquartile range) (values of plasma insulin and acute serum insulin response). Hepatic glucose
production and glucose disposal rates are expressed as mg  kg body mass1  min1 in the fasting state and during insulin infusion. Values
of plasma insulin were logarithmically transformed before statistical analysis, and their effect sizes are presented as the increase/decrease
in percent. P values and effect sizes were calculated using a mixed model adjusted for sex, age, and BMI. The additive model includes a
random-effects term for twin pair membership and a fixed-effects term for zygosity. Acute serum insulin response 0–10 min, hepatic glucose
production, and glucose disposal rate are calculated as described elsewhere (18) and in the online appendix.
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DISCUSSION
We and others have recently demonstrated that the
MTNR1B is a genetic determinant of FPG and type 2
diabetes (8–10). Our present refinement of the association
signal based on direct genotyping of data in more than
11,300 individuals within the LD block that includes
MTNR1B supports the conclusion from the in silico search
by Prokopenko et al. (9) that the intronic variant
rs10830963 may be the source of the association signal on
FPG and type 2 diabetes.
Of novelty, the G-allele of rs10830963 is associated with
increased risk of i-IFG in a population-based sample of
middle-aged Danes. Also, associations were found be-
tween the G-allele and the combined IFG/IGT phenotype
as well as with overt type 2 diabetes. In contrast, the
G-allele of MTNR1B rs10830963 tended to decrease the
risk of i-IGT, suggesting that the minor allele of rs10830963
predisposes to type 2 diabetes via a state of i-IFG and not
through increased postprandial plasma glucose levels as is
a major feature of individuals with i-IGT. This interpreta-
tion of results is supported by the finding that the G-allele
of rs10830963 was not associated with any estimates of
insulin resistance, which is a well-known pathophysiolog-
ical feature of individuals with i-IGT, but not in individuals
with i-IFG (22).
To further evaluate the underlying metabolic phenotype,
we examined quantitative traits related to glucose ho-
meostasis in the Inter99 and the Haguenau cohorts. In
both of these population samples, we showed associations
between the G-allele and decreased oral glucose–stimu-
lated serum insulin release, indicating that carriers of the
diabetogenic risk allele in MTNR1B may have pancreatic
-cell impairments relative to their level of plasma
glucose.
These results were further substantiated in a subset of
young healthy Danes, where the same allele of MTNR1B
rs10830963 was associated with a decreased acute serum
insulin response as well as a decreased disposition index
after an intravenous glucose load.
The results are in line with recent results (10,23) em-
phasizing the effect of the variant in pancreatic -cell
function. After intravenous injection of tolbutamide,
which stimulates insulin release directly through the ATP-
sensitive potassium channel, the insulin response of the
risk allele carriers was indistinguishable from that of the
wild-type carriers. These findings may be related to a
stimulus-dependent effect of the variant, suggesting an
allele-specific glucose insensitivity of the pancreatic
-cells localized upstream of the ATP-sensitive potassium
channel. Obviously, this hypothesis needs further testing
in a clinical-physiological setting.
The study of elderly Danish twins undergoing an IVGTT
and a hyperinsulinemic-euglycemic clamp confirmed the
association between the MTNR1B risk allele and an im-
paired first-phase insulin release after an intravenous
glucose challenge. In addition, we demonstrated a reduced
suppression of hepatic glucose production during the
hyperinsulinemic-euglycemic clamp documenting hepatic,
but not peripheral, insulin resistance. This is consistent
with the results and indirect suggestions in another recent
study reporting insulin resistance when indirectly as-
sessed during oral glucose ingestion in MTNR1B risk allele
carriers (23). It has previously been proposed that abnor-
mal diurnal rhythms in endogenous glucose production
are a major contributor to fasting hyperglycemia in type 2
diabetes (2). The extent to which hepatic insulin resis-
tance contributes to the elevated FPG level in carriers of
the risk alleles is uncertain. However, in a population of
young twins, we observed a tendency toward elevated
basal hepatic glucose production (P  0.06, data not
shown) in the absence of hepatic insulin resistance during
clamps. The twin data also suggest that age may play a role
for the phenotypic presentation of a disproportionately
elevated hepatic glucose production in carriers of the risk
allele of MTNR1B. Yet, we recognize that the results from
the present twin studies may be chance findings due to the
limited size of the study populations, the amount of tests
made, and the lack of correction for multiple hypothesis
testing.
Surprisingly, we observed differences in BMI when
stratifying according to rs10830963 among young healthy
Danes and among elderly Danish twins. Because the
results occur in opposite directions and since we do not
demonstrate any difference in BMI in the much larger
Inter99 study, we argue, however, that these findings may
be due to random chance, and consequently, we adjust for
BMI to correct for these differences between the genotype
groups.
Rs10830963 is located at mid-distance from exon 1 (	5.6
Kb) and exon 2 (5.9 Kb) of MTNR1B in a nonconserved
sequence across species (http://www.bx.psu.edu/miller_lab).
Lyssenko et al. (10) have reported an increased MTNR1B
expression in human pancreatic islets in rs10830963 G-allele
carriers, although the effect was only significant in individu-
als older than 45 years. In silico analyses do not predict any
potential consequence of the change from C to G at this
position on mRNA splicing (http://www.tigr.org/tdb/
GeneSplicer/gene_spl.html). Nonetheless, additional studies
are necessary to fully understand the molecular and physio-
logical impact of rs10830963, or any unidentified rare and
potentially causal variants in high LD with rs10830963.
In summary, the refinement at the MTNR1B locus shows
that the intronic rs10830963 is the variant that exhibits the
tightest associations with FPG and type 2 diabetes risk.
Importantly, the G-allele of rs10830963 confers risk of
diabetes through a stage of i-IFG and a decrease of oral
and intravenous glucose-stimulated insulin release, sug-
gesting a pancreatic -cell dysfunction.
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